Glucocorticoid Sparing of Benralizumab in Asthma: Letter

Glucocorticoid Sparing of Benralizumab in Asthma: Letter

Nair et al. (June 22 issue)1 found in the ZONDA trial that the median blood eosinophil counts fell dramatically after treatment with benralizumab. In a previous trial, Bleecker et al.2 found that blood eosinophil counts were reduced by benralizumab treatment. To avoid bias, what was done to prevent...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 2017-09, Vol.377 (12), p.1204-1205
Hauptverfasser: Öztürk, Aktaş Özge, Şekerel, Bülent E, Fuat, Kalyoncu A
Format: Artikel
Sprache:eng
Schlagworte:
Asthma
Blood
Cytokines
Drug therapy
Leukocytes (eosinophilic)
Monoclonal antibodies
Smoking
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Nair et al. (June 22 issue)1 found in the ZONDA trial that the median blood eosinophil counts fell dramatically after treatment with benralizumab. In a previous trial, Bleecker et al.2 found that blood eosinophil counts were reduced by benralizumab treatment. To avoid bias, what was done to prevent unmasking of the trial-group assignment to the investigators by means of the patients' eosinophil counts?
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMc1709523